Clinical trials: Human Immunodeficiency Virus 1 Positive
HIV (Human Immunodeficiency Virus), HPV
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South Africa
Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general…
- Conditions
- HIV (Human Immunodeficiency Virus), HPV, Cervical Precancer, Cervical Neoplasia
- Trial name
- NCT07645378
- Testing
- Thermal ablation (TA) with 1 probe, Thermal ablation (TA) with 2 probes
- Where
- South Africa
- Volunteers
- 200 people
- Sponsor
- Fred Hutchinson Cancer Center
HIV Infections
Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children
The purpose of this study is to see if PEG-Intron is safe and tolerated when given to children, to see how much gets into the blood and how long it stays in the blood, and to see how well it works to reduce viral load (level of…
- Trial name
- NCT00006325
- Testing
- Peginterferon alfa-2b
- Where
- 15 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study to Investigate the Cardiovascular Safety of Apricitabine in Healthy Subjects
The purpose of this study is to confirm that apricitabine does not induce any clinically significant effect upon electrocardiogram (ECG) parameters at doses consistent with the maximum exposure expected to occur in clinical…
- Trial name
- NCT00334659
- Testing
- apricitabine
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Avexa
HIV, HIV Infections
Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir…
- Trial name
- NCT01780506
- Testing
- E/C/F/TAF, E/C/F/TDF
- Where
- 117 sites in United States, Australia and 10 more
- Volunteers
- 872 people
- Sponsor
- Gilead Sciences